NEW YORK, NY--(Marketwire - Aug 2, 2012) - The following is an investment opinion on Immunovative, Inc. (OTCBB: IMUN), Dendreon (NASDAQ: DNDN), MannKind (NASDAQ: MNKD) and NewLink Genetics (NASDAQ: NLNK). Immunovative, Inc. (OTCBB: IMUN) has announced their ImmuNews newsletter has been published and available to the public at www.imuninfo.com. ImmuNews is designed to educate and inform our shareholders and followers of happenings in the rapidly developing field of cancer immunotherapy and provide updated information on the progress Immunovative is bringing to the market.
Notable milestones that ImmuNews points out that the company anticipates reaching this year are the clearance by the Thailand FDA of AlloStim™ Phase II/III breast cancer trials and AlloVax™ Phase I/II head and neck cancer trials. The company's team in Thailand has been managing clinical research collaboration with the National Cancer Institute of Thailand working towards clearance of these trials.
Companies like Dendreon (NASDAQ: DNDN), MannKind (NASDAQ: MNKD) and NewLink Genetics (NASDAQ: NLNK) along with Immunovative are all exploring ways to apply the body's natural immune system to fight and reject cancer and other diseases by inducing, enhancing or suppressing the immune response.
To read the ImmuNews Newsletter, please visit www.imuninfo.com
This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid IO Circuit one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.